Evaluation of Human Chorionic Gonadotropin (HCG) Therapeutic Results in Patients With Unilateral cryptorchidism (Undescended Testis)

Farzaneh Sharifiaghdas1, Sepideh Sharifiaghdas2, Esmaeil R. Maleki1, Behzad Narouie3, *, Abdolsamad Shikhzadeh1, Sarvenaz Mehrabi4
1 Department of Urology, Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Pediatrics, Torfeh General Hospital, Tehran, Iran
3 Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran
4 Department of Emergency, School of Medicine, Arak University of Medical Sciences, Arak, Iran

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 9780
Abstract HTML Views: 1648
PDF Downloads: 739
ePub Downloads: 494
Total Views/Downloads: 12661
Unique Statistics:

Full-Text HTML Views: 5209
Abstract HTML Views: 763
PDF Downloads: 522
ePub Downloads: 309
Total Views/Downloads: 6803

Creative Commons License
© 2020 Sharifiaghdas et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran, Tel: +989391837853; Email:



Cryptorchidism or undescended testis is an evolutionary defect where one or both testes fail to descend into the scrotum. HCG causes the testes to fail, possibly due to weight gain, an increase in testicular vasculature, and stimulating the testosterone and di-hydro-testosterone. The present study has been conducted to evaluate the therapeutic effects of HCG on patients with unilateral cryptorchidism.


In a prospective descriptive study, 211 patients of 8 months to 7 years old with unilateral cryptorchidism whose parents refused surgery received HCG therapy. The patients were followed up 1 month, 3months, and 12 months after the first injection. They were examined in terms of the location of testes, possible relapses, sides of undescended testes, treatment complications, and HCG therapeutic results.


Four weeks after the first injection, 160 patients (75.12%) out of 211 cases had the descent of testes into the inguinal canal and the scrotum. 69.5% of non-palpable abdominal testes descended into the inguinal canal, 69.7% of patients with inguinal testes, 78% of patients with supra inguinal testes and 100% of patients with retractile testis experienced the descent of testes into the scrotum.


The therapeutic response to HCG was successful in more than 50% of the cases in all the groups. Therefore, the need for performing surgical procedures on children with unilateral cryptorchidism would be decreased and they can be treated by a cost-effective and less invasive method. Moreover, at least one-year follow-up of the patients is required to ensure outcomes of the treatment.

Keywords: Cryptorchidism, HCG, Undescended testis, Pediatric urology, Therapeutic response, Invasive method.